title: [Influence of preoperative antithrombotic therapy on clinicopathological parameters in patients with lung cancer].
abstract: Cancer is known to promote its own development/proliferation and protect itself against attacks from immune system cells by activating the blood coagulation system. However, antithrombotic therapy inhibits the blood coagulation system. We investigated the blood coagulation system-mediated influence of preoperative antithrombotic therapy on the clinicopathological parameters of lung cancer. In patients who underwent antithrombotic therapy, there was a significant association between prothrombin time-international normalized ratio (PT-INR and positive findings on a thoracic lavage cytodiagnosis (p = 0.02). In these patients, the proportion of those with positive findings on a thoracic lavage cytodiagnosis was significantly higher than in those who did not undergo antithrombotic therapy (P = 0.0003). These results suggest that cancer progression is promoted by antithrombotic therapy through the inhibition of the blood coagulation system.
authors.affiliation: Department of Thoracic Surgery, Ehime Prefectural Central Hospital, Matsuyama, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Sawada
authors.forename: H
authors.initials: H
authors.lastname: Watanabe
authors.forename: H
authors.initials: H
authors.lastname: Sengyoku
authors.forename: T
authors.initials: T
authors.lastname: Shirafuji
authors.forename: T
authors.initials: T
authors.lastname: Nagayasu
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018450:Disease Progression; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects*; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011300:Preoperative Care / Q000009:adverse effects
chemical_list: D005343:Fibrinolytic Agents